Index
RUT
Market Cap
1.66B
Enterprise Value
1.24B
Income
-247.73M
Sales
413.80M
Book/sh
-1.16
Cash/sh
4.36
Employees
749
IPO
Dec 05, 1995
P/E
-
Forward P/E
-
PEG
-
P/S
4.02
P/B
-
P/C
2.31
P/FCF
-
EV/EBITDA
-
EV/Sales
3.00
Quick Ratio
2.30
Current Ratio
2.33
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-1.52
EPS next Y
-0.03
EPS next Q
-0.35
EPS this Y
-122.99%
EPS next Y
94.79%
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
-17.24% 18.76%
EPS Y/Y TTM
-158.19%
Sales Y/Y TTM
-61.64%
EPS Q/Q
-153.98%
Sales Q/Q
-76.30%
Insider Own
4.97%
Insider Trans
0.00%
Inst Own
65.21%
Inst Trans
0.26%
ROA
-21.62%
ROE
-
ROIC
-241.68%
Gross Margin
78.65%
Oper. Margin
-28.82%
Profit Margin
-59.87%
SMA20
-10.12%
SMA50
-3.63%
SMA200
8.45%
Trades
Shs Outstand
164.82M
Shs Float
156.76M
52W High
13.39 -24.69%
52W Low
6.20 62.58%
Volatility
7.48% 10.09%
ATR (14)
0.87
RSI (14)
44.88
Beta
2.65
Rel Volume
0.65
Avg Volume
6.27M
Volume
4,061,779
Perf Week
3.92%
Perf Month
-4.91%
Perf Quarter
36.03%
Perf Half Y
25.37%
Perf YTD
50.00%
Perf Year
19.57%
Perf 3Y
54.60%
Perf 5Y
-93.23%
Perf 10Y
-65.00%
Prev Close
10.47
Price
10.08
Change %
-3.72%
Analysts 10 incl. previous ratings
Rating Distribution 5 Buy · 2 Hold · 3 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Oct 24, 2025 Resumed C Cantor Fitzgerald
Overweight $18 +78.6% Aug 28, 2025 Resumed H H.C. Wainwright
Buy $10 -0.8% Aug 20, 2025 Downgrade B BofA Securities
Neutral → Underperform $7 -30.6% Jun 17, 2025 Initiated C Citigroup
Sell $6 -40.5% Feb 28, 2025 Initiated B BTIG Research
Buy $19 +88.5% Jul 30, 2024 Downgrade J JP Morgan
Neutral → Underweight $8 -20.6% May 10, 2024 Upgrade J JP Morgan
Underweight → Neutral May 10, 2024 Upgrade B BofA Securities
Underperform → Neutral $4 → $12 +19.0% Aug 09, 2023 Upgrade R B. Riley Securities
Neutral → Buy $15 +48.8% Apr 20, 2023 Downgrade T TD Cowen
Outperform → Market Perform $55 → $10 -0.8% Mar 01, 2023 Downgrade R B. Riley Securities
Buy → Neutral $29 → $10 -0.8% Jan 09, 2023 Reiterated R B. Riley Securities
Buy $74 → $37 +267.1% Dec 30, 2022 Reiterated H H.C. Wainwright
Buy $207 → $110 +991.3% Dec 02, 2022 Initiated J Jefferies
Hold Sep 22, 2022 Downgrade J JP Morgan
Neutral → Underweight $132 → $27 +167.9% May 20, 2022 Initiated B BofA Securities
Underperform $35 +247.2% Feb 23, 2022 Reiterated R B. Riley Securities
Buy $315 → $265 +2,529.0% Feb 22, 2022 Resumed J Jefferies
Buy $198 +1,864.3% Jan 21, 2022 Initiated C Cowen
Outperform $150 +1,388.1% May 12, 2021 Downgrade J JP Morgan
Overweight → Neutral $285 → $161 +1,497.2%
Show Previous Ratings
Oct-29-26 11:57AM
09:37AM
08:00AM
Oct-16-26 05:28PM
03:36PM
10:23PM
Loading…
Oct-12-26 10:23PM
Oct-09-26 08:09PM
04:13PM
Oct-07-26 06:26AM
Oct-06-26 05:04PM
04:48PM
03:21PM
Oct-05-26 11:34PM
07:42PM
Sep-02-26 05:00PM
06:34PM
Loading…
Aug-28-26 06:34PM
02:42PM
01:58PM
08:30AM
07:59AM
Aug-26-26 02:48PM
Aug-19-26 02:54PM
02:46PM
01:37PM
10:16AM
Aug-06-26 07:19PM
05:29PM
09:54AM
08:05AM
08:00AM
04:03PM
Loading…
Aug-03-26 04:03PM
Jul-30-26 07:00AM
Jun-01-26 04:00PM
May-11-26 10:54AM
(Yahoo Finance Video)
-6.03%
May-07-26 04:00PM
May-06-26 08:08AM
(Associated Press)
+15.56%
08:00AM
Apr-29-26 04:00PM
Apr-08-26 07:49AM
Mar-30-26 08:00AM
Mar-03-26 09:00AM
Feb-27-26 02:20PM
12:40PM
08:26AM
06:43AM
01:54AM
(New feeds test provider finance)
12:31AM
12:07AM
Feb-26-26 04:30PM
04:11PM
03:55PM
02:19PM
12:15PM
12:10PM
08:46AM
08:17AM
(Associated Press Finance)
08:06AM
08:00AM
Feb-25-26 06:09AM
Feb-23-26 12:00PM
10:33AM
09:07AM
Feb-19-26 08:00AM
Feb-17-26 09:00AM
Feb-11-26 05:45PM
Feb-06-26 09:00AM
Feb-03-26 05:45PM
Jan-31-26 07:58AM
Jan-29-26 08:50AM
Jan-28-26 05:45PM
03:00AM
Jan-26-26 12:16PM
09:00AM
Jan-22-26 05:45PM
01:03AM
Jan-21-26 03:40PM
10:06AM
07:25AM
(Pharmaceutical Technology)
05:38AM
Jan-20-26 12:53PM
10:42AM
09:59AM
(The Wall Street Journal)
07:15AM
Jan-15-26 06:19PM
(Pharmaceutical Technology)
-5.01%
Jan-14-26 05:45PM
08:19AM
Jan-13-26 03:23PM
09:00AM
Jan-12-26 11:27AM
Jan-07-26 08:00AM
Jan-05-26 05:45PM
Jan-04-26 10:39PM
Jan-02-26 11:01AM
Jan-01-26 05:43PM
Dec-30-25 09:00AM
Dec-19-25 09:00AM
Dec-11-25 01:01PM
Dec-08-25 09:00AM
Dec-05-25 05:05PM
Dec-02-25 09:40AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Ruxandra Draghia Akli Former Officer May 27 '26 Proposed Sale 11.01 21,383 235,412 May 27 04:42 PM Ruxandra Draghia Akli Former Officer May 07 '26 Proposed Sale 9.87 30,000 296,083 May 07 05:03 PM Newton Charles W. Director Apr 25 '26 Option Exercise 0.00 9,520 0 9,520 Apr 28 05:00 PM Shiver John W. Director Mar 10 '26 Option Exercise 0.00 7,947 0 7,947 Mar 12 05:00 PM Kelly James Patrick EVP, CFO and Treasurer Mar 07 '26 Option Exercise 0.00 12,223 0 136,503 Mar 09 06:13 PM Kelly James Patrick EVP, CFO and Treasurer Mar 03 '26 Option Exercise 0.00 43,167 0 145,130 Mar 05 06:04 AM Jacobs John C President and CEO Mar 03 '26 Option Exercise 0.00 150,167 0 264,130 Mar 05 06:03 AM O'Hara Elaine EVP, Chief Strategy Officer Mar 03 '26 Option Exercise 0.00 56,334 0 157,071 Mar 05 06:02 AM Casey Mark J EVP, Chief Legal Officer Mar 03 '26 Option Exercise 0.00 37,500 0 101,445 Mar 05 06:01 AM Draghia-Akli Ruxandra EVP, Research & Development Mar 03 '26 Option Exercise 0.00 26,667 0 34,876 Mar 05 06:00 AM Jacobs John C President and CEO Mar 01 '26 Option Exercise 0.00 83,333 0 264,130 Mar 03 09:37 PM Kelly James Patrick EVP, CFO and Treasurer Mar 01 '26 Option Exercise 0.00 58,666 0 130,299 Mar 03 09:35 PM O'Hara Elaine EVP, Chief Strategy Officer Mar 01 '26 Option Exercise 0.00 59,600 0 111,706 Mar 03 09:34 PM Casey Mark J EVP, Chief Legal Officer Mar 01 '26 Option Exercise 0.00 4,000 0 65,159 Mar 03 09:33 PM Jacobs John C President and CEO Jan 23 '26 Option Exercise 0.00 83,197 0 219,929 Jan 26 07:57 PM Casey Mark J EVP, Chief Legal Officer Dec 11 '25 Option Exercise 0.00 41,899 0 73,972 Dec 15 04:01 PM Draghia-Akli Ruxandra Section 16 Nov 11 '25 Option Exercise 0.00 14,257 0 14,257 Nov 13 05:23 PM
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
President Mr. John Charles Jacobs M.B.A.
Executive VP Mr. James Patrick Kelly C.F.A.
J.D. Mr. Mark J. Casey Esq.
Executive VP & Chief Strategy Officer Ms. Elaine O'Hara
Executive VP & COO Mr. Richard P. Crowley